Acuitas Investments’s Lifecore Biomedical LFCR Stock Holding History

Acuitas Investments’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-273,845	Closed	-$2.52M	–	69
2021 Q3	$2.52M	Buy	273,845 +56,128	+26%	+$611K	1.1%	47
2021 Q2	$2.45M	Hold	217,717	–	–	1.22%	43
2021 Q1	$2.31M	Sell	217,717 -31,153	-13%	-$350K	1.32%	34
2020 Q4	$2.7M	Sell	248,870 -49,228	-17%	-$509K	1.75%	23
2020 Q3	$2.9M	Buy	+298,098	New	+$2.84M	2.03%	17
2018 Q3	$2.42M	Buy	168,005 +63,809	+61%	+$882K	3.45%	17
2018 Q2	$1.55M	Buy	104,196 +72,315	+227%	+$1M	3.46%	19
2018 Q1	$416K	Buy	+31,881	New	+$419K	3.31%	19

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Acuitas Investments's LFCR Position: Q4 2021 in Review

Acuitas Investments sold out of Lifecore Biomedical (LFCR) in Q4 2021, closing a stake of 273,845 shares — an estimated $2.52M sold.

Acuitas Investments first reported a position in LFCR in Q1 2018 and held it in 8 quarters. The position peaked at $2.9M in Q3 2020. 98 funds tracked by Wall St. Rank hold LFCR as of Q4 2021.

Acuitas Investments reported no remaining Lifecore Biomedical position as of Q4 2021 after selling out during the quarter.
Acuitas Investments sold 273,845 Lifecore Biomedical shares in Q4 2021, an estimated $2.52M.
Acuitas Investments first reported a position in Lifecore Biomedical in Q1 2018 and held it in 8 quarters.
Acuitas Investments's Lifecore Biomedical position peaked at $2.9M in Q3 2020.
98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2021.

Based on Acuitas Investments's 13F filing for Q4 2021, filed 8 Feb 2022.